Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 6/20 | 0.50 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.50 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.50 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.50 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | RAF1 | P04049 | 11/20 | 0.48 |
| ▸ | BRAF | P15056 | 10/20 | 0.48 |
| ▸ | NAMPT | P43490 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4727827 | 0.89 | MAPK14 (0.56) | MAPK14MAPK13HSPB1MAPK12MAPK11 | |
| SCHEMBL4729392 | 0.87 | MAPK14 (0.54) | MAPK14MAPK13HSPB1MAPK12MAPK11 | |
| SCHEMBL4727078 | 0.86 | RAF1 (0.50) | MAPK14MAPK13HSPB1MAPK12MAPK11 | |
| SCHEMBL4847527 | 0.86 | RAF1 (0.47) | MAPK14MAPK13HSPB1MAPK12MAPK11 | |
| SCHEMBL4728328 | 0.85 | RAF1 (0.54) | MAPK14RAF1BRAF | |
| SCHEMBL4727198 | 0.84 | RAF1 (0.51) | MAPK14RAF1BRAF | |
| SCHEMBL4781805 | 0.84 | RAF1 (0.47) | RAF1BRAF | |
| SCHEMBL4781325 | 0.83 | RAF1 (0.55) | RAF1BRAF | |
| SCHEMBL4727293 | 0.83 | RAF1 (0.55) | MAPK14RAF1BRAF | |
| SCHEMBL4783075 | 0.82 | PLAU (0.42) | MAPK14MAPK13MAPK12MAPK11RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008021388-A1 | HETEROARYL DERIVATIVES AS CYTOKINE INHIBITORS | KEMIA, INC. (US) | 2008-02-21 | — | — | WO | disclosed |